SillaJen Inc Market Cap ($184.78 Million)
Market Cap & Net Worth: SillaJen Inc (215600)
SillaJen Inc market cap. SillaJen Inc (KQ:215600) has a market capitalization of $184.78 Million (₩272.67 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #16623 globally and #614 in its home market, demonstrating a -7.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SillaJen Inc's stock price ₩1974.00 by its total outstanding shares 138129836 (138.13 Million). Also see how efficiently does SillaJen Inc generate cash for how efficiently the company converts equity into cash flow.
SillaJen Inc Market Cap History (2016–2026)
SillaJen Inc market cap history from 2016 to 2026. Data shows change from $1.15 Billion to $184.78 Million (-16.57% CAGR). Check current stock price of SillaJen Inc for real-time trading data and today's change.
Index Memberships
SillaJen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.09% | #213 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.09% | #213 of 1384 |
Weight: SillaJen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SillaJen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SillaJen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SillaJen Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.06x
SillaJen Inc's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.15 Billion | $5.29 Billion | -$74.04 Billion | 0.22x | N/A |
| 2017 | $8.10 Billion | $6.86 Billion | -$57.02 Billion | 1.18x | N/A |
| 2018 | $6.37 Billion | $7.71 Billion | -$56.24 Billion | 0.83x | N/A |
| 2020 | $1.05 Billion | $1.67 Billion | -$47.82 Billion | 0.63x | N/A |
| 2022 | $603.89 Million | $5.01 Billion | -$25.26 Billion | 0.12x | N/A |
| 2023 | $522.45 Million | $3.94 Billion | -$20.37 Billion | 0.13x | N/A |
| 2024 | $234.96 Million | $3.93 Billion | -$26.53 Billion | 0.06x | N/A |
Competitor Companies of 215600 by Market Capitalization
Companies near SillaJen Inc in the global market cap rankings as of November 4, 2026. Also see SillaJen Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to SillaJen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of SillaJen Inc (2016–2026)
Market capitalization of SillaJen Inc from 2016 to today. Between 2016 and today, SillaJen Inc's market cap moved from $1.15 Billion to $ 184.78 Million, with a yearly change of -16.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩184.78 Million | -43.68% |
| 2025 | ₩328.10 Million | +39.64% |
| 2024 | ₩234.96 Million | -55.03% |
| 2023 | ₩522.45 Million | -13.49% |
| 2022 | ₩603.89 Million | -42.40% |
| 2020 | ₩1.05 Billion | -16.84% |
| 2019 | ₩1.26 Billion | -80.20% |
| 2018 | ₩6.37 Billion | -21.39% |
| 2017 | ₩8.10 Billion | +605.66% |
| 2016 | ₩1.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of SillaJen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $184.78 Million USD |
| MoneyControl | $184.78 Million USD |
| MarketWatch | $184.78 Million USD |
| marketcap.company | $184.78 Million USD |
| Reuters | $184.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more